Exelixis' Lead-In Trial Design Evaluates Cabozantinib Disease Activity Against Multiple Cancers At 12 Weeks
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel adaptive randomized discontinuation design tested cabozantinib in nine tumor types, isolated best opportunities faster than traditional randomization.